Table 1.
Clinical characteristics of emphysema patients and control individuals with and without AAT-deficiency.
| Subject group characteristics | Control subjects M-AAT n= 20 | Healthy subjects Z-AAT n = 10 | COPD patients Z-AAT n = 10 | COPD patients M-AAT n = 10 |
| Male/Female | 11/9 | 5/5 | 5/5 | 5/5 |
| Age (years) | 53 ± 9.6 | 47.4 ± 11 | 57 ± 12 | 59.4 ± 6.7 |
| Smoking history: | ||||
| Never smokers | 9 | 6 | 3 | 0 |
| Exsmokersa | 10 | 3 | 6 | 8 |
| Smokers b | 1 | 1 | 1 | 2 |
| FEV1 % of predictedc | 95.9 ± 17 | 94 ± 12 | 43 ± 13 | 37 ± 16 |
| FVC % of predicted | 92.8 ± 17 | 94 ± 14 | 63 ± 12 | 50 ± 15 |
| FEV1/FVC% ratio | 76 ± 8 | 77 ± 10 | 50 ± 15 | 40 ± 20 |
| Medication | ||||
| No medication | 20 | 6 | - | - |
| Inhaled corticosteroids | - | 3 | 7 | 10 |
| Bronchodilatators | - | - | 10 | 8 |
| Diuretics | - | - | 3 | 3 |
| Continuous oxygen | - | - | 1 | 1 |
| Anti-inflammatory | - | - | - | - |
| Anti-depressants | - | 1 | - | 1 |
a – exsmokers, stopped smoking at least 3 month before the study. b – current smokers. c – measured after bronchodilatation (terbutaline (1 mg)). Values are expressed as mean ± SD.